Clinical Trials
25
Active:1
Completed:12
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:1
Phase 2:1
+3 more phases
Drug Approvals
257
TGA:257
Drug Approvals
MediHerb Rhodiola & Schisandra (495585)
- Product Name
- MediHerb Rhodiola & Schisandra
- Approval Date
- Jul 1, 2025
TGA
MediHerb Horsechestnut Complex (490209)
- Product Name
- MediHerb Horsechestnut Complex
- Approval Date
- May 28, 2025
TGA
Eagle Clinical Tresos B Professional + (490112)
- Product Name
- Eagle Clinical Tresos B Professional +
- Approval Date
- May 27, 2025
TGA
Eagle Clinical Tresos PRO Neurocrine (490110)
- Product Name
- Eagle Clinical Tresos PRO Neurocrine
- Approval Date
- May 27, 2025
TGA
Eagle Clinical Tresos B Professional + (489429)
- Product Name
- Eagle Clinical Tresos B Professional +
- Approval Date
- May 21, 2025
TGA
- Prev
- 1
- 2
- 3
- 4
- 5
- 26
- Next
Clinical Trials
Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials
Not Applicable
14 (60.9%)Phase 4
4 (17.4%)Phase 3
2 (8.7%)Early Phase 1
1 (4.3%)Phase 1
1 (4.3%)Phase 2
1 (4.3%)Implementing Low-Barrier HCV Treatment in a Jail Setting
Phase 4
Recruiting
- Conditions
- HEPATITIS C (HCV)IncarcerationInjection Drug UseImplementation Science
- Interventions
- Other: Community Health Worker
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Lifespan
- Target Recruit Count
- 40
- Registration Number
- NCT06953479
- Locations
- 🇺🇸
Rhode Island Department of Corrections, Cranston, Rhode Island, United States
Injectable Buprenorphine in Prison: a Preference Trial
Phase 4
Not yet recruiting
- Conditions
- Opioid Use DisorderIncarcerationMedications for Opioid Use DisorderBuprenorphine
- Interventions
- Drug: Brixadi (Injectable Buprenorphine)
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Lifespan
- Target Recruit Count
- 60
- Registration Number
- NCT06880718
Stress Reactivity and Mother-Infant Cardiovascular Disease Risk
Not Applicable
Not yet recruiting
- Conditions
- Infant HealthPsychophysiologyCardiovascular DiseasesCardiovascular Diseases RiskBehavioral MedicineMindfulnessMaternal HealthHypertension
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Lifespan
- Target Recruit Count
- 40
- Registration Number
- NCT06805799
- Locations
- 🇺🇸
Women's Medicine Collaborative, Lifespan, Providence, Rhode Island, United States
Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews
Recruiting
- Conditions
- Opioid Use DisorderTreatment Adherence and ComplianceCriminal Justice
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Lifespan
- Target Recruit Count
- 25
- Registration Number
- NCT06354465
- Locations
- 🇺🇸
Rhode Island Department of Corrections, Cranston, Rhode Island, United States
Integrated Alcohol and Sexual Assault Intervention for College Men
Not Applicable
Completed
- Conditions
- Alcohol DrinkingSexual Assault
- First Posted Date
- 2023-03-17
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Lifespan
- Target Recruit Count
- 115
- Registration Number
- NCT05773027
- Locations
- 🇺🇸
Rhode Island Hospital, Providence, Rhode Island, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found